MedPath

Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success?

Not Applicable
Not yet recruiting
Conditions
Osteochondral Lesion of Talus
Interventions
Procedure: BMS alone
Biological: BMS + Bone Marrow Aspirate Concentrate
Registration Number
NCT04475341
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may be necessary. For small cystic defects the current treatment is an arthroscopic bone marrow stimulation (BMS) procedure, during which the damaged cartilage is resected and the subchondral bone is microfractured (MF), in order to disrupt intraosseous blood vessels and thereby introduce blood and bone marrow cells into the debrided lesion, forming a microfracture fibrin clot, which contains a dilute stem cell population from the underlying bone marrow. This procedure has been reported to have a 75% successful long-term outcome. Recently, the additional use of biological adjuncts has become popular, one of them being bone marrow aspirate concentrate (BMAC) from the iliac crest. BMAC consists of mesenchymal stem cells, hematopoietic stem cells and growth factors, which may therefore theoretically improve the quality of subchondral plate and cartilage repair. The current evidence for treating talar OCDs with BMS plus BMAC is limited and heterogeneous. It is unclear to what extent the treatment of talar OCDs with BMS plus BMAC is beneficial in comparison to BMS alone.

Detailed Description

Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may be necessary. For small cystic defects the current treatment is an arthroscopic bone marrow stimulation (BMS) procedure, during which the damaged cartilage is resected and the subchondral bone is microfractured (MF), in order to disrupt intraosseous blood vessels and thereby introduce blood and bone marrow cells into the debrided lesion, forming a microfracture fibrin clot, which contains a dilute stem cell population from the underlying bone marrow. This procedure has been reported to have a 75% successful long-term outcome. Recently, the additional use of biological adjuncts has become popular, one of them being bone marrow aspirate concentrate (BMAC) from the iliac crest. BMAC consists of mesenchymal stem cells, hematopoietic stem cells and growth factors, which may therefore theoretically improve the quality of subchondral plate and cartilage repair. The current evidence for treating talar OCDs with BMS plus BMAC is limited and heterogeneous. It is unclear to what extent the treatment of talar OCDs with BMS plus BMAC is beneficial in comparison to BMS alone.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
96
Inclusion Criteria
  • Patients with a symptomatic OCL of the talus who are scheduled for arthroscopic debridement and microfracture
  • OCL depth and/or diameter ≤ 15 mm on computed tomography medial-lateral and/or anterior-posterior
  • Age 18 years or older
  • Intact remaining articular cartilage of the joint Kellgren-Lawrence stage 0-1
Exclusion Criteria
  • Concomitant OCL of the tibia
  • Ankle osteoarthritis grade 2 or 3 van Dijk et al. [53]
  • Ankle fracture < 6 months before scheduled arthroscopy
  • Inflammatory arthropathy (e.g Rheumatoid arthritis)
  • History of (or current) hemopoeitic disease or immunotherapy
  • Acute or chronic instability of the ankle
  • Use of prescribed orthopaedic shoewear
  • Other concomitant painful or disabling disease of the lower limb
  • Pregnancy
  • Implanted pacemaker
  • Participation in previous trials < 1 year, in which the subject has been exposed to radiation (radiographs or CT)
  • Patients who are unable to fill out questionnaires and cannot have them filled out
  • No informed consent
  • HIV positive or hepatitis B or C infection (based on the anamnesis of the patient)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BMS without BMACBMS alone-
BMS with BMACBMS + Bone Marrow Aspirate Concentrate-
Primary Outcome Measures
NameTimeMethod
Numeric Rating Scale of Pain During Weightbearing2 years post-operatively
Secondary Outcome Measures
NameTimeMethod
FAOStwo years post-operatively

Foot and Ankle Outcome Score

NRS in rest2 years postoperatively

Numeric Rating Scale of Pain During Rest

EQ5Dtwo years post-operatively
AOFAStwo years post-operatively

American Orthopaedic Foot and Ankle Score (AOFAS)

FAAM2 years postoperatively

Foot and Ankle Ability Measure

SF-122 years postoperatively

Short-Form 12

NRS during running2 years postoperatively

Numeric Rating Scale of Pain During Running

NRS during stair-climbing2 years postoperatively

Numeric Rating Scale of Pain During Stair-Climbing

NRS during performing sports2 years post-operatively

Numeric Rating Scale of Pain During Sports

NRS during weight-bearing1 year post-operativley

Numeric Rating Scale of Pain During Weightbearing

Ankle Activity Scale (AAS)2 year post-operatively
Return to sportspost-operatively until 2 years of follow-up post-operatively
Return to workpost-operatively until 2 years of follow-up post-operatively
Radiological outcomes: CT-scan (depth, wide, length, joint space measurement)2 years postoperatively
Cost-effectivinessFrom per-operatively to post-operatively at 2 years (one period)

all relevant clinical costs will be scored through a patient diary

Cell-subset analysisper-operatively

protein analyses will be performed by Sanquin

Demographic dataPre-operatively

all kinds of demographic data will be assessed (age, gender, etc.)

ComplicationsFrom per-operatively to post-operatively at 2 years (one period)

all types of complications

Re-operationsFrom per-operatively to post-operatively at 2 years (one period)

re-operations will be assessed

Radiological outcomes: MRI scan (T2 relaxation times)2 years post-operatively
© Copyright 2025. All Rights Reserved by MedPath